Compass Therapeutics Inc. banner
C

Compass Therapeutics Inc.
NASDAQ:CMPX

Watchlist Manager
Compass Therapeutics Inc.
NASDAQ:CMPX
Watchlist
Price: 5.841 USD -2.65% Market Closed
Market Cap: $1B

During the last 3 months Compass Therapeutics Inc. insiders have not bought any shares, and have not sold any shares. The stock price has increased by 8% over this period (open performance analysis).

The last transaction was made on May 27, 2025 by Schuetz Thomas J. , who bought 21.1k USD worth of CMPX shares.

Last Transactions:
Schuetz Thomas J.
$+21.1k
Gordon Carl L
$-5.7m
Orbimed Advisors Llc
$-5.7m
Anderman Jonathan
$+30.8k
Lerner Neil
$+28.4k
Schuetz Thomas J.
$+33.7k
Schuetz Thomas J.
$+79.6k
Schuetz Thomas J.
$+77.2k
Schuetz Thomas J.
$+81k
Schuetz Thomas J.
$+83.8k
Bisker-Leib Vered
$-8.7
Bisker-Leib Vered
$-41.1k
Bisker-Leib Vered
$-62.6k
Bisker-Leib Vered
$-69.6k
Bisker-Leib Vered
$-27.4k
Orbimed Advisors Llc
$+1.3m
Gordon Carl L
$+1.3m
Schuetz Thomas J.
$+23.2k
Schuetz Thomas J.
$+34.1k
Schuetz Thomas J.
$+45.5k
Schuetz Thomas J.
$+42.5k
Schuetz Thomas J.
$+45.8k
Schuetz Thomas J.
$+39.6k
Schuetz Thomas J.
$+38.7k
Schuetz Thomas J.
$+56k
Schuetz Thomas J.
$+46.8k
Schuetz Thomas J.
$+68.7k
Schuetz Thomas J.
$+84.9k
Schuetz Thomas J.
$+60.6k
Schuetz Thomas J.
$+60.8k
Schuetz Thomas J.
$+49.9k
Schuetz Thomas J.
$+49.9k
View All Transactions

During the last 3 months Compass Therapeutics Inc. insiders have not bought any shares, and have not sold any shares. The stock price has increased by 8% over this period (open performance analysis).

The last transaction was made on May 27, 2025 by Schuetz Thomas J. , who bought 21.1k USD worth of CMPX shares.

Sold
0-3
months
0 USD
0
3-6
months
0 USD
0
6-9
months
0 USD
0
9-12
months
11.4m USD
2
Bought
0-3
months
No Insider Transactions
0
0 USD
3-6
months
No Insider Transactions
0
0 USD
6-9
months
1
21.1k USD
9-12
months
2
59.2k USD

Compass Therapeutics Inc.
Insider Trading Chart

Compass Therapeutics Inc.
Insiders Performance

1 Week Later 1 Month Later 3 Months Later 6 Months Later 1 Year Later
Average Return
Median Return
Win Rate

Compass Therapeutics Inc.
Last Insider Transactions

Global
Insiders Monitor

Compass Therapeutics Inc.
Glance View

Market Cap
1B USD
Industry
Biotechnology

Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. The company is headquartered in Boston, Massachusetts and currently employs 24 full-time employees. The company went IPO on 2020-11-13. Its pipeline of product candidates includes both angiogenesis-targeted agents and immune-oncology focused agents. These product candidates are designed for anti-tumor response to cancer. Its lead product candidate, CTX-471, is a monoclonal antibody agonist of CD137, a co-stimulatory receptor on immune cells. Its second product candidate, CTX-8371, is a bispecific antibody that simultaneously targets both PD-1 and PD-L1, the targets of checkpoint inhibitor antibodies. In addition to CTX-471 and CTX-8371, It is also developing a portfolio of bispecific and monoclonal antibody product candidates, which are in preclinical development. Its product candidate, CTX-009, is an anti-DLL4 x VEGF-A bispecific antibody, which has added to its pipeline through Trigr Therapeutics, Inc. (TRIGR).

CMPX Intrinsic Value
2.758 USD
Overvaluation 53%
Intrinsic Value
Price
C

What is Insider Trading?

Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.

While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.

Why is Insider Trading Important?

It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.

However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.

Peter Lynch

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett